IPInés Portillo-Calderón

Inés Portillo-Calderón

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Inés Portillo-Calderón has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative analysis of disk diffusion and microscan versus broth microdilution methods for determining antimicrobial susceptibility of cefepime and piperacillin-tazobactam in Escherichia coli isolates carrying bla OXA-1

    by Marta Carretero-Ledesma, Carlos Saúco-Carballo, Ana Velázquez Escudero, Inmaculada López-Hernández, Inés Portillo-Calderón, Lorena López-Cerero, José Manuel Rodríguez-Martínez, Jesús Rodríguez Baño, Álvaro Pascual, Fernando Docobo-Pérez

    Routine susceptibility testing often misses resistance in bla OXA-1 -producing E. coli , risking therapeutic failure. Among 165 clinical isolates from the Spanish multicenter cohort, MicroScan and disk diffusion versus reference broth microdilution yielded suboptimal categorical agreement (73.9%–86.7%) for piperacillin-tazobactam (PTZ) and cefepime (FEP). MicroScan PTZ very major errors (30%) indicate resistance underestimation; disk diffusion PTZ major errors (23%) and both methods FEP major errors (8.3%–13.8%) indicate resistance overestimation. These errors justify cautious interpretation of routine susceptibility results.

  • Open Access

    Erratum for Recacha et al., “Characterization of a bla KPC-3 -carrying plasmid in a clinical isolate of Klebsiella pneumoniae belonging to the emerging successful clone ST147”

    by Esther Recacha, Mercedes Delgado-Valverde, Marina R. Pulido, Elena Pérez-Nadales, Patricia Pérez-Palacios, Inés Portillo-Calderón, Juan Manuel Sánchez-Calvo, Irene Gracia-Ahufinger, Álvaro Pascual

  • Open Access

    Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations

    by Lucía Sánchez-Peña, Salud Rodríguez-Pallares, Pablo Aja-Macaya, Tania Blanco-Martín, Lucía González-Pinto, Gloria Pérez-Rodríguez, Christophe Le Terrier, Inés Portillo-Calderón, Esther Recacha, Cristina Riazzo, et al.

    Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94 Escherichia coli isolates producing β-lactamases under wild-type and low-permeability conditions, (ii) 300 genetically diverse clinical Enterobacterales isolates producing the three main carbapenemase types (KPC-like, OXA-48-like, and metallo-β-lactamases), and (iii) two collections of isolates producing mechanisms of resistance to β-lactam/β-lactamase inhibitor combinations, such as KPC variants or PBP3 insertions combined with metallo-β-lactamases (MBLs). The MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined by reference broth microdilution and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines, using the breakpoint of the β-lactam alone for not yet approved combinations. Resistance mechanisms of all clinical isolates were analyzed by whole genome sequencing. Meropenem/xeruborbactam had the broadest spectrum against the isogenic collection, although higher MICs were noted for transformants producing IMP-23, SPM-1, and NDM enzymes (these latter only when produced under low-permeability conditions). Meropenem/xeruborbactam displayed the most potent activity against the collection of 300 clinical strains (MIC 50/90 ≤0.06/≤0.06 mg/L). Xeruborbactam restored meropenem activity against the strains carrying resistance mechanisms to β-lactam/β-lactamase inhibitor combinations, including strains producing KPC variants or MBLs in combination with additional chromosomal alterations (MIC range: ≤0.06–0.25 and ≤0.06–4 mg/L, respectively). Our findings highlight the potential of xeruborbactam in combination with meropenem as a promising treatment against carbapenemase-producing Enterobacterales, including strains with emerging resistance to other β-lactam/β-lactamase inhibitor combinations.


  • Open Access

    Characterization of a bla KPC-3 -carrying plasmid in a clinical isolate of Klebsiella pneumoniae belonging to the emerging successful clone ST147

    by Esther Recacha, Mercedes Delgado-Valverde, Marina R. Pulido, Elena Pérez-Nadales, Patricia Pérez-Palacios, Inés Portillo-Calderón, Juan Manuel Sánchez-Calvo, Irene Gracia-Ahufinger, Álvaro Pascual

    Klebsiella pneumoniae ST147 has emerged as a successful clone able to efficiently disseminate a number of carbapenemases, including bla KPC . This study compared a representative bla KPC-3 -carrying plasmid of an ST147 clone with plasmids that usually harbor bla KPC-3 belonging to the high-risk clone ST512. Five clinical isolates of KPC-3-producing K. pneumoniae belonging to ST147 isolated in Southern Spain were analyzed. The first ST147 isolate detected was compared with two previous isolates of K. pneumoniae ST512/KPC-3 and KPC-3-encoding plasmid pKpQIL as reference plasmid. Microdilution, disk diffusion, β-CARBA test, and NG-Test CARBA 5 were used for antimicrobial susceptibility analysis and phenotypic characterization of the isolates according to EUCAST guidelines. Molecular characterization was performed using pulsed-field gel electrophoresis (PFGE)- Xba I, sequenced (by Illumina and Oxford Nanopore) and annotated with open-source databases (CGE tools and RAST). Plasmid incompatibility groups were analyzed using PlasmidFinder; BRIG was used to compare the bla KPC-3 -harboring plasmids from three of the selected clinical isolates with each other and with pKpQIL. Clinical isolates of ST147/KPC-3 showed resistance to β-lactams, fluoroquinolones, and aminoglycosides. Clinical isolates ST147/KPC-3 and ST512/KPC-3 had identical PFGE patterns in each clone. Plasmid replicon analysis showed a plasmid with the formula IncFII (K2:A-:B-) in the ST512 isolates, identical to pKpQIL; the ST147 isolates harbored IncFII (K1:A-:B-), although the genetic environment of bla KPC-3 was the same as pKpQIL, which is Tn 4401 _IS Kpn7 upstream of bla KPC-3 and IS Kpn6 downstream of bla KPC-3 . Plasmids harboring bla KPC-3 in ST147 and ST512 are different, although differences are subtle. The genetic environment of bla KPC-3 in the different sequence types is very conservative and identical to pKpQIL. IMPORTANCE: The successful spread of bla KPC is primarily due to the dissemination of K. pneumoniae isolates belonging to high-risk clonal complex 258 (ST258, ST11, and ST512); however, new clones are emerging globally as the ST147 clone. In this study, we compare the genetic environment of a representative bla KPC-3 -carrying plasmid of an ST147 clone with plasmids that usually harbor bla KPC-3 belonging to the high-risk clone ST512. Plasmids harboring bla KPC-3 detected in ST512 and ST147 were different; however, the close genetic environments of bla KPC-3 in the different plasmids (ST147 and ST512) remained conserved.


  • Open Access

    Performance of the BD Phoenix CPO detect assay for the detection and classification of OXA-48 producing- Escherichia coli that do not coproduce ESBL/p AmpC

    by Fátima Galán-Sánchez, Inés Portillo-Calderón, Manuel Rodriguez-Iglesias, Álvaro Pascual, Lorena López-Cerero

    Reliable detection of OXA-48-like enzymes in routine antimicrobial susceptibility testing is difficult, especially if the isolate does not coproduce other beta-lactamases. The BD Phoenix™ Emerge panel includes the CPO Detect Test (CPO-T), which allows simultaneous antimicrobial susceptibility testing and carbapenemase detection and characterization. We evaluated the accuracy of detection and classification of carbapenemases determined by CPO-T against a characterized set of OXA-48-producing Escherichia coli isolates that do not co-produce ESBL/pAmpC, and BD Phoenix™ for rapid antimicrobial susceptibility testing. A total of 51 E. coli isolates were included All the isolates were sequenced using Illumina and analyzed using Resfinder and CARD for resistance determinants, MLSTfinder for typing and Clermont Phylotyper for phylotypes. CPO-T was performed within the BD Phoenix™ NMIC-502 panel. Disk diffusion, with readings at 4, 6, 8 and 24 hours, was performed as reference method (RDD). The CPO-T detected carbapenemase activity in 100% of the isolates within 7 hours of incubation and 42 (82.4%) isolates were correctly assigned to the class D Ambler. For all isolates and antibiotics, BD Phoenix™ provided definitive susceptibility results in less than 8 hours in 64.6% of cases compared to 58.2% with RDD. Overall categorical agreement was 90.7% and 5.9% very major, 6.2% major and 3.2% minor errors were observed. Our results demonstrate that CPO-T is a reliable tool for the detection of OXA-48 in E. coli isolates that do not co-produce ESBL/p AmpC without the need for additional testing, and that BD Phoenix™ provides rapid results for the antibiotics most commonly used in empirical treatment. IMPORTANCE: Detection of OXA-48-like enzymes in isolates that do not co-produce other beta-lactamases in routine antimicrobial susceptibility testing is difficult, and studies on these types of isolates are scarce. Our study analyzes the performance of the BD Phoenix™ Emerge panel, which includes the CPO detection test (CPO-T), in a characterized set of OXA-48-producing Escherichia coli isolates that do not co-produce ESBL/pAmpC, and also provide information about time to results of this system.

  • Open Access

    Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

    by Mercedes Delgado-Valverde, Inés Portillo-Calderón, Manuel Alcalde-Rico, M. Carmen Conejo, Carmen Hidalgo, Carlos del Toro Esperón, Álvaro Pascual

    Purpose: Relebactam is a novel β-lactamase inhibitor, which, when combined with imipenem/cilastatin, is active against both class A and class C β-lactamases. To evaluate in vitro antimicrobial activity of imipenem/relebactam against a collection of recent clinical isolates of carbapenem-non-susceptible P. aeruginosa and K. pneumoniae ST258 and ST512 KPC producers belonging to different lineages from hospitals in Southern Spain. Methods: Six hundred and seventy-eight isolates were tested: 265 K. pneumoniae (230 ST512/KPC-3 and 35 ST258/KPC-3) and 413 carbapenem-non-susceptible P. aeruginosa. Imipenem, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, ceftolozane/tazobactam, meropenem, amikacin, ciprofloxacin, colistin, and ceftazidime/avibactam were used as comparators against P. aeruginosa. Against K. pneumoniae ceftazidime, cefepime, aztreonam, and ceftolozane/tazobactam were not tested, and tigecycline was studied instead. MICs were determined in duplicate by broth microdilution according to EUCAST guidelines. Results: Imipenem/relebactam displayed potent in vitro activity against both sequence types of KPC-3-producing K. pneumoniae. MIC50 and MIC90 values were 0.25 mg/L and 1 mg/L, respectively, with percent of susceptible isolates >97%. Only three K. pneumoniae ST512/KPC-3 isolates and one ST258/KPC-3 were resistant to imipenem/relebactam. Relebactam sensitized 98.5% of K. pneumoniae isolates resistant to imipenem. The activity of imipenem/relebactam against P. aeruginosa was moderate (susceptibility rate: 62.7%). Analysis of the acquired and mutational resistome of isolates with high levels of resistance to imipenem/relebactam has not shown a clear association between them. Conclusion: Imipenem/relebactam showed excellent activity against K. pneumoniae KPC-3. The activity of imipenem/relebactam against imipenem-resistant P. aeruginosa was moderate.


  • Open Access

    In Vitro Activity of Cefiderocol Compared to Other Antimicrobials against a Collection of Metallo-Beta-Lactamase-Producing Gram-Negative Bacilli from Southern Spain

    by M. Delgado-Valverde, I. Portillo-Calderón, E. Recacha, P. Pérez-Palacios, A. Pascual

    This article demonstrates the efficacy of cefiderocol against a large collection of well-characterized metallo-beta-lactamase-producing isolates, some of them even producing double carbapenemases. Furthermore, cefiderocol activity is compared to other novel broad-spectrum antimicrobials with activity against carbapenemases.


  • Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant Escherichia coli Strains in a Hollow-Fiber Infection Model

    by I. Portillo-Calderón, M. Ortiz-Padilla, B. de Gregorio-Iaria, V. Merino-Bohorquez, J. Blázquez, J. Rodríguez-Baño, J. M. Rodríguez-Martínez, A. Pascual, F. Docobo-Pérez

    Objectives: To evaluate human-like intravenous doses of fosfomycin (8g/Q8h) and amikacin (15mg/kg/Q24h) efficacy in monotherapy and in combination against six fosfomycin-heteroresistant Escherichia coli isolates using a hollow-fiber infection model (HFIM). Materials and methods: Six fosfomycin-heteroresistant E. coli isolates (4 with strong mutator phenotype) and the control strain E. coli ATCC 25922 were used. Mutant frequencies for rifampin (100mg/L), fosfomycin (50 and 200mg/L) and amikacin (32mg/L) were determined. Fosfomycin and amikacin MICs were assessed by agar dilution (AD), gradient strip (GSA) and broth microdilution (BMD) assays. Fosfomycin and amikacin synergies were studied by checkerboard and time-kill assays at different concentrations. Fosfomycin (8g/Q8h) and amikacin (15mg/kg/Q24h) efficacy alone and in combination were assessed using a HFIM. Results: Five isolates were resistant to fosfomycin by AD and BMD, but all susceptible by GSA. All isolates were considered susceptible to amikacin. Antibiotic combinations were synergistic in two isolates and no antagonism was detected. In time-kill assays, all isolates survived under fosfomycin at 64mg/L, although, at 307mg/L, only the normomutators and two hypermutators survived. Four isolates survived under 16mg/L amikacin and none at 45mg/L. No growth was detected under combination conditions. In HFIM, fosfomycin and amikacin monotherapies failed to sterilise bacterial cultures, however, fosfomycin and amikacin combination showed a rapid eradication. Conclusions. There may be a risk of treatment failure of fosfomycin-heteroresistant E. coli isolates using either amikacin or fosfomycin in monotherapy. These results support that the combination amikacin-fosfomycin can rapidly decrease bacterial burden and prevent the emergence of resistant subpopulations against fosfomycin-heteroresistant strains.


  • Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli

    by Inés Portillo-Calderón, Miriam Ortiz-Padilla, Jose Manuel Rodríguez-Martínez, Belen de Gregorio-Iaria, Jesús Blázquez, Jesús Rodríguez-Baño, Alvaro Pascual, Fernando Docobo-Pérez

    Objectives: To explore the effect of combining defects in DNA repair systems with the presence of fosfomycin-resistant mechanisms to explain the mechanisms underlying fosfomycin heteroresistance phenotypes in Enterobacteriaceae.Materials and methods: We used 11 clinical Escherichia coli isolates together with isogenic single-gene deletion mutants in the E. coli DNA repair system or associated with fosfomycin resistance, combined with double-gene deletion mutants. Fosfomycin MICs were determined by gradient strip assay (GSA) and broth microdilution (BMD). Mutant frequencies for rifampicin (100 mg/L) and fosfomycin (50 and 200 mg/L) were determined. Using two starting inocula, in vitro fosfomycin activity was assessed over 24 h in growth (0.5–512 mg/L) and time–kill assays (64 and 307 mg/L).Results: Strong and weak mutator clinical isolates and single-gene deletion mutants, except for ΔuhpT and ΔdnaQ, were susceptible by GSA. By BMD, the percentage of resistant clinical isolates reached 36%. Single-gene deletion mutants showed BMD MICs similar to those for subpopulations by GSA. Strong mutators showed a higher probability of selecting fosfomycin mutants at higher concentrations. By combining the two mechanisms of mutation, MICs and ranges of resistant subpopulations increased, enabling strains to survive at higher fosfomycin concentrations in growth monitoring assays. In time–kill assays, high inocula increased survival by 37.5% at 64 mg/L fosfomycin, compared with low starting inocula.Conclusions: The origin and variability of the fosfomycin heteroresistance phenotype can be partially explained by high mutation frequencies together with mechanisms of fosfomycin resistance. Subpopulations should be considered until clinical meaning is established.


  • Molecular insights into fosfomycin resistance inEscherichia coli

    by M. Ballestero-Téllez, F. Docobo-Pérez, I. Portillo-Calderón, J. M. Rodríguez-Martínez, L. Racero, M. S. Ramos-Guelfo, J. Blázquez, J. Rodríguez-Baño, A. Pascual

    Objectives: Fosfomycin activity in Escherichia coli depends on several genes of unknown importance for fosfomycin resistance. The objective was to characterize the role of uhpT, glpT, cyaA and ptsI genes in fosfomycin resistance in E. coli. Methods: WT E. coli BW25113 and null mutants, ΔuhpT, ΔglpT, ΔcyaA, ΔptsI, ΔglpT-uhpT, ΔglpT-cyaA, ΔglpT-ptsI, ΔuhpT-cyaA, ΔuhpT-ptsI and ΔptsI-cyaA, were studied. Susceptibility to fosfomycin was tested using CLSI guidelines. Fosfomycin mutant frequencies were determined at concentrations of 64 and 256 mg/L. Fosfomycin in vitro activity was tested using time–kill assays at concentrations of 64 and 307 mg/L (human Cmax). Results: Fosfomycin MICs were: WT E. coli BW25113 (2 mg/L), ΔglpT (2 mg/L), ΔuhpT (64 mg/L), ΔcyaA (8 mg/L), ΔptsI (2 mg/L), ΔglpT-uhpT (256 mg/L), ΔglpT-cyaA (8 mg/L), ΔglpT-ptsI (2 mg/L), ΔuhpT-cyaA (512 mg/L), ΔuhpT-ptsI (64 mg/L) and ΔptsI-cyaA (32 mg/L). In the mutant frequency assays, no mutants were recovered from BW25113. Mutants appeared in ΔglpT, ΔuhpT, ΔcyaA and ΔptsI at 64 mg/L and in ΔuhpT and ΔcyaA at 256 mg/L. ΔglpT-ptsI, but not ΔglpT-cyaA, ΔuhpT-cyaA or ΔuhpT-ptsI, increased the mutant frequency compared with the highest frequency found in each single mutant. In time–kill assays, all mutants regrew at 64 mg/L. Initial bacterial reductions of 2–4 log10 cfu/mL were observed for all strains, except for ΔuhpT-ptsI, ΔglpT-uhpT and ΔuhpT-cyaA. Only ΔglpT and ΔptsI mutants were cleared using 307 mg/L. Conclusions: Fosfomycin MIC may not be a good efficacy predictor, as highly resistant mutants may appear, depending on other pre-existing mutations with no impact on MIC.